Salbutamol delivered via a new multi-dose dry powder inhaler is as safe and efficacious as a pressurised metered dose inhaler in children aged 6-12 years Source: Eur Respir J 2002; 20: Suppl. 38, 501s Year: 2002
Formoterol delivered via a new multi-dose dry powder inhaler is safe and efficacious in adolescents aged 12-18 years Source: Eur Respir J 2002; 20: Suppl. 38, 501s Year: 2002
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
In-use in vitro performance of formoterol fumarate dihydrate powder for inhalation (6 and 12 µg/dose) delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
A comparison of once daily (evening) versus twice daily budesonide therapy from a new multi-dose dry powder inhaler versus twice daily therapy from a conventional dry powder inhaler in children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001
Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
In vitro delivery of formoterol via a novel multi-dose dry powder inhaler, at clinically relevant inspiratory flow rates Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003
The effectiveness of inhaled steroids by metered dose inhaler with aerochamber and face mask for children ages 6 months to 4 years Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002
Development of formoterol fumarate dihydrate powder for inhalation (6 µg and 12 µg per dose) delivered through a multi dose dry powder inhaler (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI) Source: Eur Respir J 2004; 24: Suppl. 48, 310s Year: 2004
Urinary cortisol levels following 400 mcg budesonide twice daily from a novel multi-dose dry powder inhaler compared to a conventional dry powder inhaler in children Source: Eur Respir J 2001; 18: Suppl. 33, 289s Year: 2001
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004
Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001
The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Bioequivalence of two ciclesonide dosing regimen (4 puffs of 200μg vs. 16 puffs of 50μg using an MDI) Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006